<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="iso-abbrev">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Clinical cancer research : an official journal of the American Association for Cancer Research</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-0432</issn>
        <issn pub-type="epub">1557-3265</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC8228505</article-id>
        <article-id pub-id-type="pmcid-ver">PMC8228505.1</article-id>
        <article-id pub-id-type="pmcaid">8228505</article-id>
        <article-id pub-id-type="pmcaiid">8228505</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1691679</article-id>
        <article-id pub-id-type="pmid">33795256</article-id>
        <article-id pub-id-type="doi">10.1158/1078-0432.CCR-20-4707</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1691679</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1691679</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sihag</surname>
              <given-names initials="S">Smita</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nussenzweig</surname>
              <given-names initials="SC">Samuel C.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Walch</surname>
              <given-names initials="HS">Henry S.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hsu</surname>
              <given-names initials="M">Meier</given-names>
            </name>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>See Tan</surname>
              <given-names initials="K">Kay</given-names>
            </name>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sanchez Vega</surname>
              <given-names initials="F">Francisco</given-names>
            </name>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chatila</surname>
              <given-names initials="WK">Walid K.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>De La Torre</surname>
              <given-names initials="S">Sergio</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Patel</surname>
              <given-names initials="A">Assem</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Janjigian</surname>
              <given-names initials="YY">Yelena Y.</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Maron</surname>
              <given-names initials="S">Steven</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ku</surname>
              <given-names initials="GY">Geoffrey Y.</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Tang</surname>
              <given-names initials="LH">Laura H.</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hechtman</surname>
              <given-names initials="J">Jaclyn</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Shah</surname>
              <given-names initials="PM">Pari M.</given-names>
            </name>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Wu</surname>
              <given-names initials="A">Abraham</given-names>
            </name>
            <xref ref-type="aff" rid="A8">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jones</surname>
              <given-names initials="DR">David R.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Molena</surname>
              <given-names initials="D">Daniela</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Berger</surname>
              <given-names initials="MF">Michael F.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065</aff>
        <aff id="A2"><label>2</label>Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065</aff>
        <aff id="A3"><label>3</label>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065</aff>
        <aff id="A4"><label>4</label>Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065</aff>
        <aff id="A5"><label>5</label>Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065</aff>
        <aff id="A6"><label>6</label>Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065</aff>
        <aff id="A7"><label>7</label>Department of Gastroenterology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065</aff>
        <aff id="A8"><label>8</label>Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065</aff>
        <author-notes>
          <corresp id="CR1"><bold>Corresponding author</bold> Smita Sihag, M.D. M.P.H., 1275 York Avenue, Office C882, New York, NY 10065, 212-639-7609, <email>sihags@mskcc.org</email></corresp>
          <fn fn-type="COI-statement" id="FN1">
            <p id="P31"><bold>Conflicts of interest:</bold> Geoffrey Y. Ku has the following relationships: research funding from Arog, Daiichi, and Zymeworks; research funding/consulting from AstraZeneca, Bristol Myers Squibb, Merck, and Pieris; and consulting from Eli Lilly. Abraham J. Wu has received research grants (institutional) from CivaTech Oncology, personal fees from AstraZeneca, and a travel grant from AlphaTau Medical. Yelena Y. Janjigian has financial relationships with Eli Lilly, ASCO, Michael J. Hennessy Associates, Paradigm Medical Communications, Zymeworks, AstraZeneca, Daiichi Sankyo, ONO Pharma, Merck, and Bristol Myers Squibb. David R. Jones serves as a senior medical advisor for Diffusion Pharmaceuticals and a consultant for AstraZeneca and Merck. Daniela Molena serves as a consultant for Johnson &amp; Johnson, Urogen, and Boston Scientific. All other authors have no conflicts to report.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="epub">
          <day>01</day>
          <month>4</month>
          <year>2021</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <day>15</day>
          <month>6</month>
          <year>2021</year>
        </pub-date>
        <volume>27</volume>
        <issue>12</issue>
        <issue-id pub-id-type="pmc-issue-id">384492</issue-id>
        <fpage>3491</fpage>
        <lpage>3498</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>06</day>
              <month>06</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>15</day>
              <month>12</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>15</day>
              <month>12</month>
              <year>2021</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-06-11 05:25:28.327">
              <day>11</day>
              <month>06</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1691679.pdf"/>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Purpose:</title>
            <p id="P1">To delineate recurrent oncogenic driver alterations and dysregulated pathways in esophageal adenocarcinoma and to assess their prognostic value.</p>
          </sec>
          <sec id="S2">
            <title>Experimental Design:</title>
            <p id="P2">We analyzed a large cohort of patients with lower esophageal and junctional adenocarcinoma, prospectively sequenced by MSK-IMPACT with high-quality clinical annotation. Patients were subdivided according to treatment intent, curative vs. palliative, which closely mirrored clinical staging. Genomic features, alterations, and pathways were examined for association with overall survival using Cox proportional hazard models, adjusted for relevant clinicopathologic factors knowable at the time of diagnosis.</p>
          </sec>
          <sec id="S3">
            <title>Results:</title>
            <p id="P3">Analysis of 487 patients revealed 16 oncogenic driver alterations, mostly amplifications, present in ≥5% of patients. Patients in the palliative-intent cohort, compared to those in the curative-intent cohort, were more likely to have metastatic disease, <italic toggle="yes">ERBB2</italic> amplifications, Cell Cycle and RTK-RAS pathway alterations, as well as a higher fraction of genome altered and rate of whole-genome doubling. In multivariable analyses, <italic toggle="yes">CDKN2A</italic> alterations, <italic toggle="yes">SMAD4</italic> alterations, <italic toggle="yes">KRAS</italic> amplifications, Cell Cycle and TGFβ pathways, and overall number of oncogenic drivers were independently associated with worse overall survival. <italic toggle="yes">ERBB2</italic> amplification was associated with improved survival, presumably due to trastuzumab therapy.</p>
          </sec>
          <sec id="S4">
            <title>Conclusions:</title>
            <p id="P4">Our study suggests that higher levels of genomic instability are associated with more advanced disease in esophageal adenocarcinoma. Furthermore, <italic toggle="yes">CDKN2A</italic>, <italic toggle="yes">KRAS</italic>, and <italic toggle="yes">SMAD4</italic> represent prognostic biomarkers, given their strong association with poor survival.</p>
          </sec>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
